Achieve Life Sciences Partners with Adare Pharma for Cytisinicline Manufacturing Ahead of Potential 2026 FDA Decision — Achieve Life Sciences, Inc.

Event summary

Achieve Life Sciences announced a partnership with Adare Pharma Solutions for U.S.-based manufacturing of cytisinicline, aiming to reduce supply chain risks and costs ahead of a potential commercial launch in early 2027.
The FDA accepted the cytisinicline NDA for smoking cessation with a PDUFA target action date of June 20, 2026.
Achieve completed the ORCA-OL long-term exposure trial with 334 participants, exceeding FDA requirements for safety data.
Cytisinicline received the FDA Commissioner’s National Priority Voucher for vaping cessation, expediting future review processes.
The company reported $36.4 million in cash and equivalents as of December 31, 2025, with a net loss of $54.7 million for the year.

The big picture

Achieve Life Sciences is positioning cytisinicline as a potential new standard in nicotine dependence treatment, mirroring the shift in obesity management with GLP-1 therapies. The strategic partnership with Adare Pharma underscores the company’s focus on reducing supply chain vulnerabilities ahead of a critical FDA decision. With a growing body of clinical evidence and expedited review pathways, Achieve is navigating a competitive landscape where smoking and vaping cessation remain significant unmet medical needs.

What we're watching

Regulatory Approval: Whether the FDA will approve cytisinicline for smoking cessation by the June 20, 2026 PDUFA date, given the completed safety and efficacy data.
Supply Chain Risk: How the Adare Pharma partnership will mitigate manufacturing risks, particularly after FDA observations at another cytisinicline manufacturer.
Commercialization Pace: The speed at which Achieve can scale its commercial operations, given the planned 2027 launch and ongoing market access preparations.